## Amendments to the Claims

This listing of claims will replace all prior listings of claims in the application.

## Listing of Claims

## 1.-6. (Canceled)

- 7. (New) A method of treatment of organ dysfunction following haemorrhagic shock in a human patient which comprises the step of administering to the patient reconstituted high density lipoprotein and/or a derivative thereof in pharmaceutically acceptable form.
- 8. (New) A method according to Claim 7 in which the medicament is for the treatment of end-stage organ injury or failure.
- 9. (New) A method according to Claim 7 in which the high density lipoprotein or derivative thereof is a peptide or protein derivative of the sequence of apo A-I or apo A-II, or a peptide or protein derivative functionally homologous to the active portions of apo A-I or apo A-II.
- 10. (New) A method according to Claim 8 in which the high density lipoprotein or derivative thereof is a peptide or protein derivative of the sequence of apo A-I or apo A-II, or a peptide or protein derivative functionally homologous to the active portions of apo A-I or apo A-II.
- 11. (New) A method according to Claim 7 in which the high density lipoprotein is reconstituted HDL.
- 12. (New) A method according to Claim 8 in which the high density lipoprotein is reconstituted HDL.

- 13. (New) A method according to Claim 7 in which the high density lipoprotein is native HDL.
- 14. (New) A method according to Claim 8 in which the high density lipoprotein is native HDL.